CompletedNot applicableNCT01869777

Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia

Studying Acute undifferentiated leukemia

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Wake Forest University Health Sciences
Principal Investigator: Timothy Pardee
Wake Forest University Health Sciences
Intervention: bioelectric impedance analysis(procedure)
Enrollment: 102 enrolled
Eligibility: All sexes
Timeline: 2013 – 2020

Study locations (1)

Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01869777 on ClinicalTrials.gov

Other trials for Acute undifferentiated leukemia

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE1NCT06466395
A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias
M.D. Anderson Cancer Center

See all trials for Acute undifferentiated leukemia →

← Back to all trials